today’s cyclodextrin:
CDs are currently not widely applied in vaccines, yet they have vast potential as stabilizers in cryopreservation (see Janssen Inc.’s covid vaccine) as well as a vaccine adjuvant. So far, it is mainly HPBCD that has been used for these purposes. In this early stage clinical trial, Vaxxas uses sulfobutyl-BCD in their quadrivalent influenza vaccine to preserve antigen potency during coating and storage.
Angus Forster, Adam Wheatley, Jesse Bodle, et al.
See the clinical trial details here